Patient-based transcriptome-wide analysis identify interferon and ubiquination pathways as potential predictors of influenza A disease severity. by Hoang, Long Truong et al.
Hoang, LT; Tolfvenstam, T; Ooi, EE; Khor, CC; Naim, AN; Ho, EX;
Ong, SH; Wertheim, HF; Fox, A; Van Vinh Nguyen, C; Nghiem,
NM; Ha, TM; Thi Ngoc Tran, A; Tambayah, P; Lin, R; Sangsajja,
C; Manosuthi, W; Chuchottaworn, C; Sansayunh, P; Chotpitaya-
sunondh, T; Suntarattiwong, P; Chokephaibulkit, K; Puthavathana,
P; de Jong, MD; Farrar, J; van Doorn, HR; Hibberd, ML (2014)
Patient-based transcriptome-wide analysis identify interferon and ubiquina-
tion pathways as potential predictors of influenza A disease severity.
PLoS One, 9 (11). e111640. ISSN 1932-6203 DOI: 10.1371/jour-
nal.pone.0111640
Downloaded from: http://researchonline.lshtm.ac.uk/2869433/
DOI: 10.1371/journal.pone.0111640
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
Patient-Based Transcriptome-Wide Analysis Identify
Interferon and Ubiquination Pathways as Potential
Predictors of Influenza A Disease Severity
Long Truong Hoang1*, Thomas Tolfvenstam12, Eng Eong Ooi3, Chiea Chuen Khor1, Ahmand Nazri
Mohamed Naim1, Eliza Xin Pei Ho1, Swee Hoe Ong1, Heiman F. Wertheim4, Annette Fox4, Chau Van Vinh
Nguyen5, Ngoc My Nghiem5, Tuan Manh Ha6, Anh Thi Ngoc Tran6, Paul Tambayah7, Raymond Lin7,
Chariya Sangsajja8, Weerawat Manosuthi8, Chareon Chuchottaworn9, Piamlarp Sansayunh9,
Tawee Chotpitayasunondh10, Piyarat Suntarattiwong10, Kulkanya Chokephaibulkit11,
Pilaipan Puthavathana11, Menno D. de Jong2,3, Jeremy Farrar2, H. Rogier van Doorn2, Martin
Lloyd Hibberd1
1Genome Institute of Singapore, Singapore, Singapore, 2 The Hospital for Tropical Diseases, Wellcome Trust Major Overseas Programme, Oxford University Clinical
Research Unit, Ho Chi Minh City, Vietnam, and Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom,
3Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, 4National Hospital of Tropical Diseases,
Wellcome Trust Major Overseas Programme, Oxford University Clinical Research Unit, Hanoi, Vietnam, and Centre for Tropical Medicine, Nuffield Department of Medicine,
University of Oxford, Oxford, United Kingdom, 5Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam, 6Children Hospital 2, Ho Chi Minh City, Vietnam, 7National
University Hospital, Singapore, Singapore, 8 Bamrasnaradura Infectious Disease Institute, Nonthaburi, Thailand, 9Chest Disease Institute, Nonthaburi, Thailand, 10Queen
Sirikit National Institute of Child Health, Bangkok, Thailand, 11 Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, 12 Infection Immunology,
Respiratory Infections, Karolinska Institutet, Solna, Sweden
Abstract
Background: The influenza A virus is an RNA virus that is responsible for seasonal epidemics worldwide with up to five
million cases of severe illness and 500,000 deaths annually according to the World Health Organization estimates. The
factors associated with severe diseases are not well defined, but more severe disease is more often seen among persons
aged .65 years, infants, pregnant women, and individuals of any age with underlying health conditions.
Methodology/Principal Findings: Using gene expression microarrays, the transcriptomic profiles of influenza-infected
patients with severe (N= 11), moderate (N= 40) and mild (N= 83) symptoms were compared with the febrile patients of
unknown etiology (N = 73). We found that influenza-infected patients, regardless of their clinical outcomes, had a stronger
induction of antiviral and cytokine responses and a stronger attenuation of NK and T cell responses in comparison with
those with unknown etiology. More importantly, we found that both interferon and ubiquitination signaling were strongly
attenuated in patients with the most severe outcomes in comparison with those with moderate and mild outcomes,
suggesting the protective roles of these pathways in disease pathogenesis.
Conclusion/Significances: The attenuation of interferon and ubiquitination pathways may associate with the clinical
outcomes of influenza patients.
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Introduction
The influenza A virus is an enveloped-, single-stranded,
segmented negative-sense RNA virus that is responsible for
seasonal epidemics worldwide. The World Health Organization
estimates that seasonal influenza results in up to five million cases
of severe illness and 500,000 deaths annually. The risk factors
associated with severe diseases are not well defined, but more
severe disease is more often seen among persons aged .65 years,
infants, pregnant women, and individuals of any age with
underlying health conditions [1].
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The interaction between the virus and the host genetic and
immune status clearly plays an important role in determining the
outcome of the infection [2]. In human and animal models of
seasonal influenza, influenza virus A/H5N1 (Avian Influenza A
H5N1 virus) and A/H1N1/1918 (Influenza A H1N1 1918 strain)
the cytokine levels in host respiratory secretions and serum have
been associated with disease severity and outcome [3]. Hypercy-
tokinemia was observed in humans infected with influenza virus
A/H5N1 and found to be correlated to severity and mortality [4].
The innate immune responses in humans infected with influenza
virus A/H5N1 suggest that pro-inflammatory mediators are
contributing to disease pathogenesis, with elevated blood levels
of IL-6, TNF-a, IFN-c, and sIL-2R and elevated levels of IP-10,
MCP-1, and MIG observed in patients [5]. Such responses may
contribute to acute lung injury, acute respiratory distress syndrome
(ARDS) and multi-organ failure observed in many patients.
Recently, IFITM3, an interferon-induced transmembrane protein,
has been shown to have important roles in restricting the
morbidity and mortality in mice infected with influenza virus [6].
The majority of host response studies in influenza have focused
on direct measurements of immunological markers in blood from
patients or from expression profiles in lung tissue in animal models
[3,7,8]. However, studies that have assessed the functional
interactions between gene expression profiles and individual
clinical presentation have not been performed. In this prospective
study we explored these functional interactions and linked these
data with the clinical features of patients infected with influenza
viruses in various degrees of severity to provide insights into the
pathogenesis of severe influenza.
Materials and Methods
Patient population and sample collection
Mild influenza samples and other febrile illness (OFI)
samples. Patients were recruited between January 2008 and
January 2010 from an undifferentiated fever inclusion study
(EDEN) in Singapore, focusing on early enrollment after fever
development. The EDEN study has been ongoing since 2005 [15].
Individuals eligible for inclusion gave their written consent to
participate in the study, were $18 years of age and presented #
72 h from onset of fever $38uC. Patients were tested by PCR for
influenza A and B, respiratory syncytial virus, parainfluenza 1–3,
coronavirus, metapneumovirus, enterovirus and adenovirus in
nasal swabs and for dengue virus 1–4, human parvovirus B19,
Cytomegalovirus, and Epstein Bar virus in EDTA blood. To
characterize the early transcriptional response to influenza A
infection in-vivo, we performed whole-blood transcriptional
profiling on all samples from both groups at 72 h after fever
onset, at 3–8 days and 3–4 weeks after self-reported fever onset.
The time point of the 1st, 2nd and 3rd sampling was regarded as
acute disease, defervescence and convalescence, respectively.
Moderate and severe influenza samples. Samples of
moderate and severe influenza patients were collected from a
multi-center, double-blinded, randomized control trial of standard
dose (75 mg bd or pediatric equivalent) versus double dose
(150 mg bd or pediatric equivalent) oseltamivir for the treatment
of influenza patients requiring hospitalization (Registered Clin-
icalTrials.gov: NCT00298233) [9]. The study took place across
five hospitals in Vietnam, three hospitals in Indonesia, four
hospitals in Thailand, and one in Singapore, all hospitals being
part of the Southeast Asia Infectious Disease Clinical Research
Network (SEAICRN). The primary endpoint of the trial was the
proportion of subjects with no detectable viral RNA in respiratory
swabs at day 5 as measured by RT-PCR. Whole-blood samples
were collected in PAXgene tubes on day 0, 5 and 28 of enrolment
into the study. For this study, to avoid the effect of the treatment
on the host response, only the whole blood samples collected
before oseltamivir treatment (study day 0) and at follow up (day 28)
were used.
The inclusion criteria of this study were: (i) age $1 year, (ii)
duration of illness #10 (non-H5N1) or #14 (H5N1) days, (iii)
positive result for influenza virus A or B using a rapid antigen test
or qualitative reverse transcriptase polymerase chain reaction (RT-
PCR) in a respiratory specimen, (iv) presence of at least one
respiratory symptom (cough, dyspnea or sore throat), (v) disease
requiring hospital admission, and (vi) one of the following signs of
severe influenza: (a) new infiltrate on a chest X-ray, (b) tachypnea
(respiratory rate$30 for ages$12 years, rate$40 for ages 6 to 12
years, rate $45 for ages 3 to 6 years, rate $50 for ages 1– to 3
years), (c) dyspnea (unable to speak full sentences, or use of
accessory respiratory muscles), or (d) hypoxia (arterial oxygen
saturation #92% on room air by a transcutaneous method).
Subjects infected with avian influenza virus A/H5N1 were
enrolled with any degree of severity. The exclusion criteria were:
(i) pregnancy or urine b-hCG positivity, (ii) breast feeding, (iii)
prior oseltamivir therapy for .72 hours duration or double dose
(any duration) within the past 14 days, (iv) allergy or severe
intolerance of oseltamivir, (v) creatinine clearance (CrCl) ,
10 mL/min. Severe influenza was defined as: i) requiring
mechanical ventilation or ii) presenting with severe tachypnea
((respiratory rate $30 for ages $12 years, rate $40 for ages 6 to
12 years, rate $45 for ages 3 to 6 years, rate $50 for ages 1–to 3
years)) and hypoxia (arterial oxygen saturation #92% on room air
by a transcutaneous method.
Ethics statement
The EDEN study was conducted in accordance with the
Declaration of Helsinki and approved by the National Health
Group (NHG) ethical review board (DSRB B/05/013). Individ-
uals eligible for inclusion gave their written consent to participate
in the study, and were $18 years of age. Samples of moderate and
severe influenza patients were collected from a multi-center,
double-blinded, randomized control trial of standard dose (75 mg
bd or pediatric equivalent) versus double dose (150 mg bd or
pediatric equivalent) oseltamivir for the treatment of influenza
patients requiring hospitalization (Registered ClinicalTrials.gov:
NCT00298233) [9].
Gene expression microarray
One-color array technology on the Illumina platform (Illumina
Inc, San Diego, CA, USA) was used for gene expression
microarray. In brief, whole-blood (2.5 ml) from PAXgene RNA
tubes (Qiagen, Sussex, UK) was extracted using Paxgene RNA kits
(Qiagen). Biotinylated amplified cRNA was generated by in vitro
transcription (IVT) technology using Illumina TotalPrep RNA
Amplification Kit (Ambion, Inc., Austin, TX, USA) according to
the manufacturer’s instructions. After purification, 2 mg of cRNA
was hybridized to an Illumina HumanRef-12 V4 BeadChip
(containing probes to more than 29,000 gene transcripts) at 55uC
for 18 hours following the manufacturer’s instructions (Illumina,
Inc., San Diego, CA, USA). This was followed by washing,
blocking and streptavidin-Cy3 staining steps. Finally, the chip was
scanned with an Illumina Bead Array Reader confocal scanner
and checked using Illumina QC analysis. Background subtracted
raw gene expression intensity data was exported from the
GenomeStudio software and used for further analysis.
Signatures of Severe Influenza Revealed by Gene Expression Microarray
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Data normalization
All datasets were normalized by using R (http://www.
bioconductor.org) as described below. First, the raw data was
log10 transformed before Z score transformation was performed
[10]. The Z score was calculated for each sample by subtracting
the overall mean gene intensity from the raw intensity signal for
each gene (reference). After that, this data was divided by the
standard deviation of all of the measured intensities as in the
following formula:
Zscore~ Intensity(G){Mean(intensity(G1:::Gn)
SD(G1:::Gn)
where G is any gene on the microarray and G1…Gn represents
the aggregate measure of all of the genes.
Statistical analysis
We used the Z score as the base value to identify differentially
expressed probes in comparisons between any two groups of
samples. Probes with high Z score are those highly expressed while
those with low Z score are the least expressed probes [10].
Conventional fold change calculation could be simple to
understand but at low intensities, where data is much more
variable, false positive rate could increase. In contrast, at high
intensity, where probes are significantly expressed might not be
identified. Z score transformation calculate the number of
standard deviations a particular data point is form the mean, To
identify differentially expressed probes in each group of patients, Z
ratio for each genes was calculated [10]. Z score was calculated by
dividing the mean difference in Z score between the groups by the
standard deviation of the Z score difference across all the genes.
Zratio~
Mean½Zscore(group1){Mean½Zscore(group2)
SD(ZscoredifferenceG1:::Gn)
Where G1…Gn represents the aggregate measure of all the genes.
A Z ratio of 6 1.96 is equivalent to the significant level of P
value,0.05 [10].
SAM
SAMR package for R (www.bioconductor.org) was used for the
Z-score normalized data. For comparison between acute and
convalescent samples from OFI, mild and moderate patients, two
class-paired test was used. For comparison between acute and
convalescent samples from patients with severe influenza, a two
class-unpaired test was used. The SAM procedure combines the
calculation of a t-test statistic value for each gene with subsequence
permutation (N= 1,000) analysis and the calculation of false
discovery rate (FDR). Statistic data from Z difference, Z ratio and
SAM were combined to identify the differentially expressed genes.
Significant genes were those that have SAM FDR #0.05, Z ratio
of 6 1.96.
Ingenuity Pathway analysis (IPA)
The differentially expressed genes (DEGs) were identified using
Ingenuity Pathway Analysis (IPA) (www.ingenuity.com). The IPA
database contains canonical pathways and functional gene
relationships expertly-curated from the literature which helps us
to understand the disease processes by identifying key biological
functions and novel molecular networks. DEG lists are cross-
referenced against this database to identify enriched pathways
associated with the study conditions. Significant canonical
pathways were defined as having a Fisher’s exact test P value,
Table 1. Baseline characteristics of the patients in the study.
Symptoms OFI (N=83) Mild (N=73) Moderate (N=40) Severe (N=11)
Demographic
Age, years median (range) 25 (18–70) 25 (18–69) 41.5 (5–70) 24 (19–73)
Sex, Female (%) 26 (31.3%) 24 (32.9%) 21 (52.5%) 4 (36%)
D.O.I, day median (range) 6 (3–8) 5 (3–8) 4 (1–9) 6 (2–9)
Virology
Quantitative PCR positive ND 35 (86%) 6 (55%)
Influenza PCR Ct value ND 31.52 (21.1–39.9) 34.825 (26.1–39.88)
2009 pandemic H1N1 Neg 9 (12%) 24 (60%) 6 (54.4%)
H1N1 Neg 45 (62%) 1 (2.5%) 2 (18.2%)
H3N2 Neg 19 (26%) 14 (35%) 3 (27.4%)
H5N1 Neg 0 (0%) 1 (2.5%) 0 (0%)
Hematology, median (range)
WBC (103/mL) 6.1 (1.3–18.9) 4.7 (1.4–9.5) 5.9 (1.55–6.44) 11.89 (4.6–28)
Neutrophil (103/mL) 3.45 (1.3–9.4) 2.6 (0.5–6.5) 3.67 (0.62–10.88) 9.6 (2.1–24.5)
Lymphocyte (103/mL) 2 (0.7–6.1) 1.7 (0.5–3.6) 2.19 (0.23–7.56) 3 (0.24–11.57)
HGB (g/dL) 14.6 (6.9–23.7) 14.85 (9.5–22.4) 13 (10.7–16.2) 11.7 (8.7–15.2)
HCT (%) 43.5 (21.9–81.1) 44.6 (29.8–71.6) 38.8 (32.5–44.9) 35.1 (27.8–46)
PLT (103/mL) 273 (86–513) 218 (79–370) 206 (55–345) 115 (27–250)
Values are presented in median (range); WBC: white blood cell count (normal range: 4–126103/mm3); OFI: other febrile illness; D.O.I: day of illness; HGB: hemoglobin;
HCT: hematocrit; PLT: platelet; ND: not done; Neg: negative.
doi:10.1371/journal.pone.0111640.t001
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0.05 (B–H correction). In addition to filtering by the P values, each
enriched pathways were analyzed carefully by taking into account
the ratio and the number of the gene in each pathway.
Results
Mild and OFI (Other Febrile Illness) patients
A total of 167 patients with flu-like symptoms were recruited
into the study. Of these 167 patients, 84 were infected with
influenza virus A/H1N1pdm09 (Influenza A H1N1 pandemic
2009), pre-2009 seasonal A/H1N1, H3N2 virus, rhinovirus, or co-
infected with rhinovirus and seasonal H1N1 virus. The other 83
were all pathogen-negative patients during the same time interval
and were therefore designated as the OFI group. Amongst the 84
pathogen-infected patients, those who were infected with rhino-
virus or co-infected with rhinovirus were removed. Only patients
infected with influenza A virus were used for the data analysis
(N= 73). These patients were defined as having mild influenza
because they were not hospitalized and did not present with any
symptoms of moderate or severe influenza. To match the duration
of illness of moderate and severe patients, mild influenza samples
collected at the second time point (ranging from day 3 to day 8)
and their follow-up samples (3–4 weeks after) were used. The
baseline characteristics of these patients are summarized in
Table 1 and their clinical symptoms are summarized in Table 2.
Moderate and severe influenza patients
Samples from the moderate and severe influenza patients were
collected during the same time frame (from 2007 to 2010), and a
total of 153 whole blood samples from 51 patients were collected.
Of these 51 patients, 30 patients were infected with influenza virus
A/H1N1pdm09, 17 patients with A/H3N2 virus, and three with
pre-2009 seasonal A/H1N1 and one with A/H5N1 virus. Among
the 51 patients, only 11 fulfilled the criteria for severe disease while
the 40 remaining patients were considered to have moderate
disease. Although the sample sizes are small, there does not appear
to have any correlation between severity and the infecting
influenza virus strain. The baseline characteristics of both groups
of patients are summarized in Table 1.
At the first time point, patients with severe disease were enrolled
after a median duration of illness of 5.8 days (interquartile range or
IQR of 2–9 days), and patients with moderate disease after 4.3
days (IQR 1–9 days); the distribution in days of illness prior to
enrolment was not statistically significant between both groups. At
enrolment, severe patients had significantly higher total white
blood cell counts (Table 1). When the differential white cell
counts were scrutinized, patients with severe disease had
significantly higher absolute neutrophil counts. The absolute
platelet count was also significantly lower in the patients with
severe disease.
Table 2. Clinical manifestations of the patients in the study.
Symptoms assessed in all patients
OFI
(N=84)
Mild
(N=73)
Moderate
(N=40)
Severe
(N=11)
Hospitalization, case (percentage) 0 (0%) 0 (0%) 40 (100%) 11 (100%)
Headache, case (percentage) 24 (29%) 20 (27%) 26 (65%) 7 (64%)
Diarrhea, case (percentage) 2 (2.4%) 3 (4%) 11 (28%) 2 (18%)
Nausea, case (percentage) 8 (10%) 3 (4%) 13 (33%) 2 (18%)
Vomiting, case (percentage) 1 (1.2) 0 (%) 15 (38%) 2 (18%)
cough, case (percentage) 23 (28%) 28 (38%) 39 (98%) 11 (100%)
Sore throat, case (percentage) 9 (11%) 6 (8%) 24 (60%) 5 (45%)
Symptoms that were assessed only in moderate and severe patients
Admitted to Intensive care unit, count (percentage) – – 7 (17.5%) 11 (100%)
Supplemental Oxygen, count (percentage) – – 17 (43%) 11 (100%)
Arterial Oxygen Saturation ,92%, count (percentage) – – 4 (10%) 2 (18%)
Mechanical Ventilation, count (percentage) – – 0 (0%) 7 (64%)
Severe Dyspnea, count (percentage) – – 1 (2.5%) 7 (63%)
Respiratory Rate, median (range) – – 22 (14–40) 30 (20–38)
Severe Tachypnea, count (percentage) – – 2 (5%) 6 (55%)
Temp, median (range) – – 38 (36–40.4) 39 (37.9–40.2)
Pulse, median (range) – – 90 (68–120) 118 (70–155)
Blood Pressure, median (range) – – 111.5 (90–160) 105 (60–140)
Lansky Score, median (range) – – 80 (50–100) 20 (10–60)
Abnormal Cardiovascular, count (percentage) – – 1 (2.5%) 5 (45%)
Coma, count (percentage) – – 0 (0%) 1 (9%)
Crackles, count (percentage) – – 22 (55%) 9 (82%)
Abnormal X-ray, count (percentage) – – 31 (78%) 11 (100%)
Pleural Effusion, count (percentage) – – 0 (%) 2 (18%)
doi:10.1371/journal.pone.0111640.t002
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Gene expression microarray
Using paired SAM test to compare expression profiles of acute
(N= 83) and convalescent (N=83) samples from OFI patients, we
identified 287 differentially expressed transcripts (DATs). Of these
287 transcripts, 201 were less abundant and 86 were more
abundant in acute samples. Using the same criteria, we detected
2,081 (1,316 more and 765 less abundant) DATs in acute samples
from patients with mild influenza in comparison with their
convalescent samples. When comparing acute samples from
moderate patients with the convalescent (N=40), we identified
4,108 DATs (2788 more and 1,320 less abundant). For severe
patients, because follow-up samples were available for only 7 out
of 11 patients, we performed unpaired SAM test instead of paired
SAM test in order to avoid losing samples. For this analysis, we
found 854 DATs in acute samples (430 more and 424 were less
abundant). The results of these comparisons are summarized in
Figure 1.
Up-regulated pathways. In comparison with febrile patients
with unknown aetiology, patients with influenza infections showed
strong antiviral and cytokine responses. Amongst the most
significant pathways, Toll-like receptor signaling, IL-10 signaling,
Role of PKR in Interferon Induction and Antiviral Response and
NFkB signaling were significantly up-regulated in the influenza
patients. Significant genes associated with these pathways in each
condition are summarized in Figure 2. Although the same
pathways were activated in influenza patients regardless of their
severity, different genes sets in each pathway were activated in
patients with different outcomes (Figure 2). For example, patients
with severe influenza had significant up-regulation of TLR10,
NFKBIA, IL1R2, SOCS3, IL4R, IL1R1, PROK1, ECE1,
IFNAR1, MMP9, PPP1R10 and PPP2R2A whilepatients with
moderate influenza shared similar antiviral and cytokine response
with both those with severe (TLR2, TRL4, TLR5, TLR8,
IL10RB, IL18RAP, IL18R1, MAPK13, MAPK14, FCGR1A
and IRAK3) and with mild outcomes (TLR7, TICAM3, IL1RN,
STAT1, SOCS1, JAK2, IRAK2, TNFAIP, CASP3, CCL2 and
CCR1). Genes in IL-1 signaling, IL-22 signaling, Production of
Nitric Oxide and Reactive Oxygen Species in Macrophages and
p38 MAPK signaling were only up-regulated in moderate and
severe patients (Table 3). In comparison with patients with severe
outcome, those with moderate and mild outcome were character-
ized with a significant up-regulation of protein ubiquitination,
interferon signaling pathway and Activation of IRF by Cytosolic
Pattern Recognition Receptors (Table 4). The interferon signal-
ing pathway was completely attenuated in patients with severe
influenza (only one gene was activated: IFNGR1) whereas the
pathway was strongly up-regulated in patients with moderate
(P = 1022.8, ratio 0.36, 13 genes) and mild (P= 1024.8, ratio = 0.33,
12 genes) outcomes (Figure 3). Similarly, the protein ubiquitina-
tion pathway were highly up-regulated in moderate (P = 1029,
ratio 0.26, 63 genes) and mild (P= 1027, ratio 0.16, 42 genes)
patients but was not up-regulated in those with severe outcome
(Table 4).
Many interferon-induced transmembrane (IFITM) proteins
were shown to play important roles in influenza disease outcomes.
Here, we investigated all the IFITMs and other interferon-induced
genes (64 in total) that were included on the Illumina HumanRef-
12 V4 BeadChip. Table 5 shows all the IFITMs and other
interferon-related genes and their expression levels in our patient
groups. Amongst the 72 transcripts, 30 transcripts were signifi-
cantly up-regulated in patients with moderate and mild outcomes
while none of these were significant in patients with severe
outcome or those with OFI (Table 5). Amongst the most
significant genes are IFI27, IFI44, OAS3, OAS1, OASL, IFIT1,
IFIH1, IFIT3 and DHX58 (RIG-I) which were highly up-
regulated in moderate and mild patients and down-regulated in
patients with severe outcome (Table 5).
Down-regulation pathways. T cell and NK cell related
responses were down-regulated in all groups of influenza patients
but to a weaker magnitude in those with OFI (Table 6). Natural
Killer Cell Signaling, Crosstalk between Dendritic Cells and
Natural Killer Cells, CD28 Signaling in T Helper Cells, PKCh
Signaling in T Lymphocytes were amongst the most significant
pathways. Similar to the up-regulated pathways, although the
pathway names were shared between different groups but the
genes activated in each pathway were different. NK cell response
related genes such as CD247, KIR2DL4, KIR3DL1, KIR3DL3
and KLRB1 were down-regulated only in moderate and severe
patients while genes such as KIR2DL1, KIR2DS4 and KIR3DL2
were down-regulated in all three groups of influenza patients
(Figure 4). CD244, CD3E, CD4, HLA-DMB, HLA-DPA1,
NCR3, PLD3, PRR5 and VEGFA were down-regulated only in
Figure 1. The numbers of differentially expressed transcripts (FDR 0.05, fold change .2) were observed in patients with mild and
moderate influenza in comparison with OFI and severe patients. The y-axis shows the number of differentially expressed transcripts in acute
samples for each condition on the x-axis in comparison with their convalescent samples. Up-regulated genes in the acute phase are in blue, genes
down-regulated in dark red.
doi:10.1371/journal.pone.0111640.g001
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Figure 2. Genes that were involved in Toll-like receptor signaling, IL-10 signaling, Role of PKR in Interferon Induction and Antiviral
Response and NFkB signaling pathways. The pathway names were shared between different groups but the activated genes in each pathway
were different. Differentially expressed genes (FDR ,0.05, fold change .2) were highlighted in grey.
doi:10.1371/journal.pone.0111640.g002
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patients with severe outcomes (Figure 5). Beside NK cell and T
cells related response, pathways related to the host translational
regulation such as eIF4 and p70S6K signaling, EIF2 signaling and
mTOR signaling were significantly down-regulated in all influenza
infected groups but with a stronger magnitude in patients with
mild and moderate disease.
Discussion
By investigating the transcriptional profiles of patients with a
wide range of disease severity from non-influenza fever of
unknown aetiology to mild, moderate and severe influenza, we
found that patients with confirmed influenza infections had similar
and stronger host responses in comparison with patients with fever
of unknown aetiology. The interferon response was shown to be
strongly up-regulated in influenza virus A infection [11], however,
the exact mechanism of interferon responses in different clinical
severities of influenza has not been described. Here, we found that
the interferon signaling pathway and the protein ubiquitination
pathway were attenuated in patients with fever of unknown
aetiology and patients with severe influenza manifestations
suggesting the protective roles of these pathways in the disease
mechanism. Furthermore, our data suggests that interferon
signaling pathway and other interferon-induced transmembrane
proteins (IFITMs) play important protective roles in the disease
mechanism. Amongst the IFITMs, IFITM3 has been shown to
block influenza virus entry to the cells [12] and limit the severity of
influenza virus infection in mice [13]. Our data suggests that not
only IFITM3, but other IFITMs and ISGs genes could similarly
play important roles in the disease outcomes.
Apart from the interferon pathway, the ubiquitiniation signaling
pathway was also attenuated in patients with severe outcome.
Protein ubiquitination is a post-translational process involving the
addition of ubiquitin to a protein substrate, and it plays important
roles in protein-protein interactions. For example the NS1 protein
from influenza A virus could inhibit the IFN response by inhibiting
Figure 3. Interferon signaling pathways was highly up-regulated in moderate and mild influenza patients but was attenuated in
patients with severe outcome. Up-regulated genes were highlighted in grey. IFNGR1 was the only gene that was up-regulated in severe patients
while a large number of other genes were up-regulated in moderate and mild patients.
doi:10.1371/journal.pone.0111640.g003
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Figure 4. Genes that were involved in the most significantly down-regulated pathways such as Natural Killer Cell Signaling,
Crosstalk between Dendritic Cells and Natural Killer Cells, CD28 Signaling in T Helper Cells, PKCh Signaling in T Lymphocytes. The
pathway names were shared between different groups but the activated genes in each pathway were different. Differentially expressed genes (FDR
,0.05, fold change .2) were highlighted in grey.
doi:10.1371/journal.pone.0111640.g004
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the ubiquitination of the viral RNA sensor RIG-I [14]. RIG-I is
the key host sensor for viral RNA inside the cytoplasm that
accounts for the induction of the host IFN response [15].
Ubiquitination of the CARD domain in RIG-I is essential for
the activation of IRF3 and NFkB which in turn induce the IFN
production [16] [17]. As mentioned above, ubiquitination of RIG-
I is the key process by which the host could recognize the influenza
virus RNA to induce interferon response. The attenuation of the
protein ubiquitination pathway and RIG-I could lead to the lack
of interferon response in the severe patients. It was also shown that
the host protein ubiquitination system is required for influenza
virus replication [17]. This may explain why the percentage of
patients who had virus detected at sample collection was lower in
Figure 5. Difference in expression of transcripts in T cell and NK cell signaling pathways. These transcripts were only down-regulated in
patients with severe symptoms but not in OFI, mild and moderate disease (*: P#0.05).
doi:10.1371/journal.pone.0111640.g005
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the severe group (55%) in comparison with those in the moderate
group (86%).
As mentioned, although the same pathways were up-regulated
in the patients with different severity outcomes, certain genes such
as TLR10, NFKBIA, IL1R2, SOCS3, IL4R, IL1R1, PROK1,
ECE1, IFNAR1, MMP9, PPP1R10 and PPP2R2A were up-
regulated only in the severe patients. It was shown in mouse model
that MMP9, which is capable of digesting the extracellular matrix,
was produced mainly by neutrophils and was required for
neutrophils migration to the respiratory tract in response against
viral replication [18]. The up-regulation of MMP9 in the severe
patients suggests the contribution of this gene in the disease
outcome. The up-regulation of the Suppressor of cytokine
signaling 3 (SOCS3) gene was IFNAR1-dependent and it has
negative regulatory functions to the innate immune response
which could inhibit type I interferon signaling [19]. The lack of
interferon signaling in the severe patients could be explained by
the up-regulation of SOCS3 in these patients. TLR10 has recently
been shown to play a role in innate immune response in influenza
infection and that its expression is stronger during infection by the
highly pathogenic influenza H5N1 virus [20].
Amongst the down-regulated pathways, the T cell signaling
response and NK cell responses were predominant in all influenza
patients. More interestingly, these pathways in patients with severe
disease were more predominant in comparison with patients with
mild and moderate disease. Previous studies have shown that type
I interferon response could be exploited by opportunistic
pathogens in influenza infection which in turn could increase the
host susceptibility to secondary bacterial infections such as
Streptococcus pneumoniae by negatively regulating the T cell
response [21]. We did not detect any secondary bacterial
infections in the moderate and severe patients by using both
conventional blood culture or by 16S rRNA sequencing (data not
shown). This could be due to the fact that all of the patients were
treated with antibiotics before they were recruited to the study.
Many genes involved in T cell and NK cell responses were
down-regulated in influenza infected patients regardless of their
clinical outcome, however, we found that some keys transcripts in
the T cell and NK cell signaling response were only down-
regulated in patients with severe influenza (CD244, CD3E, CD4,
CD1A, NCR3 and IL10RA) suggesting the important roles of
these transcripts in severe influenza. Previous studies have shown
that severe influenza A disease was associated with a transient NK
cell and CD8 T cell response [22,23]. Amongst the down-
regulated genes, NCR3 has been reported to show a direct
interaction with influenza viruses whereby the virus down-
regulates the cytotoxicity of NK cells mediated by this gene
[24,25]. In addition, single polymorphisms in NCR3 have been
shown to be strongly associated with decreased lung function in a
recently conducted large scale (N.48,000) genome-wide associa-
tion study of forced expiratory volume as a surrogate for lung
function [26].
Despite having relatively large sample sizes for the moderate,
mild and OFI groups, the one limitation of our study is the small
sample size of severe influenza patients that we managed to recruit
in the duration of the study. Nevertheless, we have generated a
large exploratory transcriptomic dataset in influenza disease with a
wide spectrum of severity. Although the validation of these
findings is beyond the scale of the current study, our dataset can
serve as a valuable data mine for researchers in the field to select
their own gene candidates for hypothesis testing and validation.
Taken together, by investigating the global host transcriptional
profile in influenza virus A infected patients with different clinical
outcomes, we have provided insights into the global gene
expression in influenza virus A infection. In particular, we have
revealed the attenuation of interferon and protein ubiquitination
pathways and the down-regulation of T and NK cell related
responses in patients with severe influenza virus A infections.
Lastly, we propose the following candidate genes for further
studies: MMP9, SOCS3, IFITMs, TLR10, RIG-I, CD244 and
NCR3.
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